I am a
Home I AM A Search Login

Papers of the Week

2022 May-Jun

Ann Indian Acad Neurol



Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India.


Chowdhury D, Chaudhuri JR, Ghosh P, Kulkarni R, Singh S, Thakur S, Thorat AV
Ann Indian Acad Neurol. 2022 May-Jun; 25(3):433-440.
PMID: 35936611.


EMPOwER, a 12-week, double-blind (DB), randomized, placebo-controlled study evaluated the efficacy and safety of erenumab in adult patients with episodic migraine (EM) from Asia, the Middle East, and Latin America. This study analyzes the Indian experience for the use of erunumab for prevention of episodic migraine.